In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia

American Journal of Psychiatry

Volumn 160, Issue 1, 2003, Pages 118-127

  Raedler, Thomas J ^a,b,c   Knable, Michael B ^a,b,c   Jones, Douglas W ^a,b,c   Urbina, Richard A ^a,b,c   Gorey, Julia G ^a,b,c   Lee, Kan S ^a,b,c   Egan, Michael F ^a,b,c   Coppola, Richard ^a,b,c   Weinberger, Daniel R ^a,b,c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF HAMBURG   (Germany)

^c Stanley Medical Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZILIC ACID DERIVATIVE; IODINE 123; IODOQUINUCLIDINYL BENZILATE; MUSCARINIC RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; BRAIN REGION; CADAVER; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; FEMALE; GENDER; HUMAN; IN VIVO STUDY; MALE; PATHOPHYSIOLOGY; PONS; PRIORITY JOURNAL; PROTEIN ANALYSIS; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; BRAIN; BRAIN MAPPING; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; QUINUCLIDINYL BENZILATE; RECEPTORS, MUSCARINIC; REFERENCE VALUES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0037223693     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.160.1.118     Document Type: Article

References (63)

1. Carlsson A: The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988; 1:179-186
2. Tandon R, Shipley JE, Greden JF, Mann NA, Eisner WH, Goodson JA: Muscarinic cholinergic hyperactivity in schizophrenia: Relationship to positive and negative symptoms. Schizophr Res 1991; 4:23-30
3. Tandon R, DeQuardo JR, Goodson J, Mann NA, Greden JF: Effect of anticholinergics on positive and negative symptoms in schizophrenia. Psychopharmacol Bull 1992; 28:297-302
4. Riemann D, Hohagen F, Krieger S, Gann H, Muller WE, Olbrich R, Wark HJ, Bohus M, Low H, Berger M: Cholinergic REM induction test: Muscarinic supersensitivity underlies polysomnographic findings in both depression and schizophrenia. J Psychiatr Res 1994; 28:195-210
5. Maixner S, Tandon R, Eiser A, Taylor S, DeQuardo JR, Shipley J: Effects of antipsychotic treatment on polysomnographic measures in schizophrenia: A replication and extension. Am J Psychiatry 1998; 155:1600-1602
6. O'Keane V, Abel K, Murray RM: Growth hormone responses to pyridostigmine in schizophrenia: Evidence for cholinergic dysfunction. Biol Psychiatry 1994; 36:582-588
7. Bennett JP Jr, Enna SJ, Bylund DB, Gillin JC, Wyatt RJ, Snyder SH: Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 1979; 36:927-934
8. 1 receptors is decreased in the caudateputamen of subjects with schizophrenia. Mol Psychiatry 1996; 1:54-58
9. 3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. Life Sci 1999; 64:1761-1771
10. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B: Decreased muscarinic receptor binding in subjects with schizophrenia: A study of the human hippocampal formation. Biol Psychiatry 2000; 48:381-388
11. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B: Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: A study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 2001; 158:918-925
12. Bolden C, Cusack B, Richelson E: Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 1992; 260:576-580
13. Eckelman WC, Reba RC, Rzeszotarski WJ, Gibson RE, Hill T, Holman BL, Budinger T, Conklin JJ, Eng R, Grissom MP: External imaging of cerebral muscarinic acetylcholine receptors. Science 1984; 223:291-293
14. 123IQNB and single photon emission computed tomography. Arch Neurol 1991; 48:169-176
15. Sunderland T, Esposito G, Molchan SE, Coppola R, Jones DW, Gorey J, Little JT, Bahro M, Weinberger DR: Differential cholinergic regulation in Alzheimer's patients compared to controls following chronic blockade with scopolamine: A SPECT study. Psychopharmacology (Berl) 1995; 121:231-241
16. Raedler TJ, Knable MB, Jones DW, Lafargue T, Urbina RA, Egan MF, Pickar D, Weinberger DR: In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Neuropsychopharmacology 2000; 23:56-68
17. Kay SR, Opler LA, Fiszbein A: Positive and Negative Syndrome Scale (PANSS). North Tonawanda, NY, Multi-Health Systems, 1986
18. Wyatt RJ: Practical Psychiatric Practice: Forms and Protocols for Clinical Use. Washington, DC, American Psychiatric Press, 1993
19. Lee KS, He XS, Jones DW, Coppola R, Gorey JG, Knable MB, de-Costa BR, Rice KC, Weinberger DR: An improved method for rapid and efficient radioiodination of iodine-123-IQNB. J Nucl Med 1996; 37:2021-2024
20. Aquilonius S-M, Eckernas S-A: A Colour Atlas of the Human Brain. New York, Raven Press, 1980
21. Talairach J, Tournoux P: Co-Planar Stereotaxic Atlas of the Human Brain: Three-Dimensional Proportional System. New York, Thieme Medical, 1988
22. Duvernoy HM: The Human Brain: Three-Dimensional Sectional Anatomy and MRI. Vienna, Springer-Verlag, 1991
23. Johnstone EC, Crow TJ, Ferrier IN, Frith CD, Owens DG, Bourne RC, Gamble SJ: Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychol Med 1983; 13: 513-527
24. Waddington JL, Youssef HA, Kinsella A: Mortality in schizophrenia: Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998; 173:325-329
25. Watanabe S, Nishikawa T, Takashima M, Toru M: Increased muscarinic cholinergic receptors in prefrontal cortices of medicated schizophrenics. Life Sci 1983; 33:2187-2196
26. Owen F, Cross AJ, Crow TJ, Lofthouse R, Poulter M: Neurotransmitter receptors in brain in schizophrenia. Acta Psychiatr Scand Suppl 1981; 291:20-28
27. Garcia-Rill E, Biedermann JA, Chambers T, Skinner RD, Mrak RE, Husain M, Karson CN: Mesopontine neurons in schizophrenia. Neuroscience 1995; 66:321-335
28. Karson CN, Casanova MF, Kleinman JE, Griffin WS: Choline acetyltransferase in schizophrenia. Am J Psychiatry 1993; 150: 454-459
29. McGeer PL, McGeer EG: Possible changes in striatal and limbic cholinergic systems in schizophrenia. Arch Gen Psychiatry 1977; 34:1319-1323
30. Haroutunian V, Davidson M, Kanof PD, Perl DP, Powchik P, Losonczy M, McCrystal J, Purohit DP, Bierer LM, Davis KL: Cortical cholinergic markers in schizophrenia. Schizophr Res 1994; 12:137-144
31. Gronier B, Rasmussen K: Activation of midbrain presumed dopaminergic neurones by muscarinic cholinergic receptors: An in vivo electrophysiological study in the rat. Br J Pharmacol 1998; 124:455-464
32. 2-muscarinic drugs on striatal dopamine release and metabolism: An in vivo microdialysis study comparing normal and 6-hydroxydopamine-lesioned rats. Brain Res 1993; 630:57-64
33. Bolam JP, Francis CM, Henderson Z: Cholinergic input to dopaminergic neurons in the substantia nigra: A double immunocytochemical study. Neuroscience 1991; 41:483-494
34. Gronier B, Perry KW, Rasmussen K: Activation of the mesocorticolimbic dopaminergic system by stimulation of muscarinic cholinergic receptors in the ventral tegmental area. Psychopharmacology (Berl) 2000; 147:347-355
35. Marchi M, Raiteri M: On the presence in the cerebral cortex of muscarinic receptor subtypes which differ in neuronal localization, function and pharmacological properties. J Pharmacol Exp Ther 1985; 235:230-233
36. Dewey SL, Smith GS, Logan J, Brodie JD, Simkowitz P, MacGregor RR, Fowler JS, Volkow ND, Wolf AP: Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. Proc Natl Acad Sci USA 1993; 90:11816-11820
37. Gronier B, Rasmussen K: Pertussis toxin treatment differentially affects cholinergic and dopaminergic receptor stimulation of midbrain dopaminergic neurons. Neuropharmacology 1999; 38:1903-1912
38. Fiorillo CD, Williams JT: Cholinergic inhibition of ventral midbrain dopamine neurons. J Neurosci 2000; 20:7855-7860
39. Yeomans JS: Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology 1995; 12:3-16
40. 2 dopamine receptors in drug-naive schizophrenics. Science 1986; 234:1558-1563
41. 11C]raclopride. Arch Gen Psychiatry 1990; 47:213-219
42. 123I-IBZM single photon emission computerised tomography study. Br J Psychiatry 1994; 164:16-26
43. 123I]-iodobenzamide SPECT study. Br J Psychiatry 1997; 171:574-577
44. 123I]beta-CIT. Biol Psychiatry 2000; 47:371-379
45. Laakso A, Vilkman H, Alakare B, Haaparanta M, Bergman J, Solin O, Peurasaari J, Räkköläinen V, Syvälahti E, Hietala J: Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am J Psychiatry 2000; 157:269-271
46. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB: Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996; 93:9235-9240
47. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, deBartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D: Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997; 94:2569-2574
48. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M: Increased baseline occupancy of D-2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000; 97:8104-8109
49. Muller P, Seeman P: Brain neurotransmitter receptors after long-term haloperidol: Dopamine, acetylcholine, serotonin, alpha-noradrenergic and naloxone receptors. Life Sci 1977; 21: 1751-1758
50. Ben-Barak J, Gazit H, Silman I, Dudai Y: In vivo modulation of the number of muscarinic receptors in rat brain by cholinergic ligands. Eur J Pharmacol 1981; 74:73-81
51. Misra CH, Shelat H, Smith RC: Influence of age on the effects of chronic fluphenazine on receptor binding in rat brain. Eur J Pharmacol 1981; 76:317-324
52. Theodorou A, Gommeren W, Clow A, Leysen J, Jenner P, Marsden CD: Chronic neuroleptic treatment specifically alters the number of dopamine receptors in rat brain. Life Sci 1981; 28: 1621-1627
53. Friedman E, Gianutsos G, Kuster J: Chronic fluphenazine and clozapine elicit opposite changes in brain muscarinic receptor binding: Implications for understanding tardive dyskinesia. J Pharmacol Exp Ther 1983; 226:7-12
54. 2 dopamine and muscarinic cholinergic receptors and on carbachol-stimulated phosphoinositide hydrolysis in the rat striatum. Jpn J Psychiatry Neurol 1987; 41:311-320
55. 2 dopamine and muscarinic cholinergic receptors in rat striatum. J Pharmacol Exp Ther 1988; 244:987-993
56. 2 and muscarinic receptor binding characteristics in rat brain after withdrawal of subchronic fluphenazine and sulpiride treatment. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13:247-258
57. See RE, Toga AW, Ellison G: Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats. J Neural Transm Gen Sect 1990; 82:93-109
58. Cawley TA Jr, Shickley TJ, Ruggieri MR, Luthin GR: Effect of chronic neuroleptic treatment on central and peripheral muscarinic receptors. J Pharmacol Exp Ther 1993; 267:134-139
59. Raedler TJ, Knable MB, Jones DW, Gorey JG, Lee KS, Sunderland T, Weinberger DR: Age-related changes in central muscarinic receptor availability in vivo (abstract). J Nucl Med 2000; 41(suppl):92
60. Saffen D, Mieda M, Okamura M, Haga T: Control elements of muscarinic receptor gene expression. Life Sci 1999; 64:479-486
61. Buckley NJ, Bachfischer U, Canut M, Mistry M, Pepitoni S, Roopra A, Sharling L, Wood IC: Repression and activation of muscarinic receptor genes. Life Sci 1999; 64:495-499
62. Bymaster FP, Shannon HE, Rasmussen K, Delapp NW, Mitch CH, Ward JS, Calligaro DO, Ludvigsen TS, Sheardown MJ, Olesen PH, Swedberg MD, Sauerberg P, Fink-Jensen A: Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6- (3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane. Eur J Pharmacol 1998; 356:109-119
63. Shannon HE, Hart JC, Bymaster FP, Calligaro DO, DeLapp NW, Mitch CH, Ward JS, Fink-Jensen A, Sauerberg P, Jeppesen L, Sheardown MJ, Swedberg MD: Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats. J Pharmacol Exp Ther 1999; 290:901-907